Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...

Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by T cells and macrophages to activate immune responses during infection or after trauma. IL-6 plays an important role in a number of bodily ...

Besides being an immune protein, IL-6 is also a pyrogen and is responsible for fever in autoimmune, infectious, or non-infectious diseases. IL-6 is produced in the body, wherever there is inflammation ...

Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...

Epidemiology and prognostic factors of hepatosplenic T-cell lymphoma (HSTL): An analysis of NCDB (National Cancer Database). Median (interquartile range) of IL-6 and CRP in patients before and after ...

Lowering the activity of interleukin-6 (IL-6) – a key immune signal regulating inflammatory responses in the body – could reduce the risk of cardiovascular disease without making people more ...

Vaccine immunotherapy targeting interleukin 6 (IL-6) has shown promising results in the treatment of inflammatory osteoarthritis of the knee, according to a phase 1 double-blind controlled study.

gloved hand holding blood test in lab Ziltivekimab is a narrow-spectrum fully human monoclonal antibody targeting the IL-6 ligand that is being developed specifically for atherosclerosis treatment.

Interleukin 6 receptor (IL-6r) inhibition is a promising approach for the treatment of calcium pyrophosphate deposition disease (CPPD), although no prospective studies have been conducted to date.